| Vol. 13.24 – 24 June, 2021 |
| |
|
|
| Researchers generated 42,000 genomes from multi-year time-series single-cell whole-genome sequencing of breast epithelium and primary TNBC patient-derived xenografts, revealing the nature of copy number alteration-defined clonal fitness dynamics induced by TP53 mutation and cisplatin chemotherapy. [Nature] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators found that the nonclassical histocompatibility antigen HLA-G desensitized breast cancer cells to trastuzumab by binding to the natural killer cell receptor KIR2DL4. [Signal Transduction and Targeted Therapy] |
|
|
|
| The authors showed that persistent oncogenic RAS signaling caused highly metastatic triple-negative mammary tumors in mice. The continuous signaling of oncogenic RAS played a crucial role in the cellular plasticity and maintenance of the mesenchymal and stem cell characteristics of claudin-low mammary cancer cells. [Nature Communications] |
|
|
|
| In lean and obese mice, tumor progression and immune reprogramming were quantified in breast cancer tumors treated with anti-programmed death-1 (PD-1) or control. Scientists found anti-PD-1 to be highly efficacious in obese mice by reinvigorating durable antitumor immunity. [Cell Reports] |
|
|
|
| Researchers found that the RNA-binding protein Musashi1 (Msi1) exhibited elevated expression in invasive breast tumors and promoted lung metastasis of mammary cancer cells. Suppression of Msi1 reduced invadopodia formation in mammary cancer cells. [Oncogene] |
|
|
|
| Investigators found that Doxorubicin enhanced the oncolytic effect of the M1 virus by up to 100-fold specifically in TNBC in vitro, and significantly stalled the tumor growth of TNBC in vivo, through promoting intratumoral virus replication and further triggering apoptosis in addition to necroptosis. [Oncogene] |
|
|
|
| Scientists identified delayed down-regulated genes (DDGs) in mammary cells after prolonged treatment with epidermal growth factor (EGF). The expression of these DDGs was low in mammary tumors and correlated with prognosis. [Science Signaling] |
|
|
|
| The authors used Cell Counting Kit-8, colony formation, wound healing migration, Transwell invasion, and nude mouse xenograft assays to confirm the role of the long noncoding RNA actin filament-associated protein 1 antisense RNA1 (AFAP1-AS1) in the proliferation, migration of TNBC cells in vitro and in vivo. [Cell Death & Disease] |
|
|
|
| Researchers utilized breast cancer patient-derived xenografts from the Mayo Breast Cancer Genome Guided Therapy Study to establish two immortalized, genomically unique breast cancer cell lines. [npj Breast Cancer] |
|
|
|
| Scientists showed that GPx type 1 (GPx1) played a key regulatory role in the apoptosis signaling pathway. The absence of GPx1 augmented TNF-α-induced apoptosis in various RIPK3-negative cancer cells by markedly elevating the level of cytosolic H2O2, which was derived from mitochondria. [Experimental & Molecular Medicine] |
|
|
|
| The authors investigated how the spatiotemporal receptor organization at the cell surface was modulated by biparatopic designed ankyrin repeat proteins (bipDARPins), which potently induced apoptosis in human epidermal growth factor receptor 2-addicted breast cancer cell lines. [Communications Biology] |
|
|
|
| Researchers investigated the therapeutic efficacy of the combination of 131I-trastuzumab and lanatoside C for inhibition of human epidermal growth factor receptor 2 (HER2) positive tumor progression in NCI-N87 xenograft model. [Scientific Reports] |
|
|
|
|
| The authors describe the cellular and molecular features of the luminal cell lineage expressing estrogen receptor-α (ERα) and provide an overview of the transgenic mouse models impacting ERα signaling, highlighting the pivotal role of ERα in mammary gland morphogenesis and function and its implication in the tumorigenic processes. [Cellular and Molecular Life Sciences] |
|
|
|
| Personalized immunotherapy has recently been proposed as a potential complementary medicine with immunotherapy and chemotherapy for overcoming breast cancer (BC). Investigators discuss the brief association of these methods and future directions in BC immunotherapy. [International Immunopharmacology] |
|
|
|
|
| ImmunityBio, Inc. announced it has received FDA authorization to conduct a Phase Ib/II open-label study to evaluate the safety and preliminary efficacy of its superagonist Anktiva and PD-L1 targeted high-affinity natural killer (t-haNK) cells in combination with standard chemo and Trodelvy, in subjects with advanced TNBC. [ImmunityBio, Inc.] |
|
|
|
|
| August 12 – 14, 2021 Busan, South Korea |
|
|
|
|
|
| Mayo Clinic Health System – Rochester, Minnesota, United States |
|
|
|
| University of Michigan – Ann Arbor, Michigan, United States |
|
|
|
| Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
| Icahn School of Medicine at Mount Sinai – New York City, New York, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
|